SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY

被引:5
作者
Matucci-Cerinic, M. [1 ]
Schulze-Koops, H. [2 ]
Buch, M. [3 ]
Kavanaugh, A. [4 ]
Allanore, Y. [5 ]
Kucharz, E. J. [6 ]
Babic, G. [7 ]
机构
[1] Univ Florence, Florence, Italy
[2] Ludwig Maximillans Univ, Munich, Germany
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Paris Descartes Univ, Cochin Hosp, Paris, France
[6] Med Univ Silesia, Katowice, Poland
[7] Hexal AG, Holzkirchen, Germany
关键词
D O I
10.1136/annrheumdis-2018-eular.1368
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FRI0129
引用
收藏
页码:609 / 609
页数:1
相关论文
共 2 条
  • [1] The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
    Griffiths, C. E. M.
    Thaci, D.
    Gerdes, S.
    Arenberger, P.
    Pulka, G.
    Kingo, K.
    Weglowska, J.
    Hattebuhr, N.
    Poetzl, J.
    Woehling, H.
    Wuerth, G.
    Afonso, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (04) : 928 - 938
  • [2] Kavanaugh A, 2017, ARTHRITIS RHEUMATOL, V69